新型冠状病毒

EU loosens defence of pharma groups on Covid vaccine patents

Softened approach to intellectual property would allow emerging markets to manufacture own treatments

The EU has proposed that developing countries be allowed to manufacture Covid-19 vaccines, softening its defence of drug companies’ intellectual property.

Valdis Dombrovskis, trade commissioner, who had opposed a plan to reduce IP protection, has now said he could support limited exemptions.

India and South Africa are pushing for the abolition of IP controls, so domestic producers could replicate products from the likes of AstraZeneca and Pfizer without paying them royalties.

您已阅读24%(478字),剩余76%(1477字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×